Lotte Holdings said on June 11 that its healthcare and biopharmaceutical-focused corporate venture capital (CVC) arm has invested in Swiss-based antibody drug conjugate (ADC) startup ClearideBio Therapeutics. The company participated as lead investor in ClearideBio’s pre-seed financing round, with the…
To read the full story
Related Article
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





